# Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects

> **NCT00230516** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 100 (—)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Nexium
- **DRUG:** Prevacid

## Key facts

- **NCT ID:** NCT00230516
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** —
- **Final completion:** 2006-02
- **Target enrollment:** 100 (—)
- **Last updated:** 2013-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00230516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00230516, "Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00230516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*